ArticleNucleic acids research2023
G-quadruplex-based CRISPR photoswitch for spatiotemporal control of genomic modulation.
Article in Nucleic acids research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- Cas-regulation-targeting chimera enables selective and tunable control of CRISPR/Cas12a.Nucleic acids research · 2026Article
- Steric regulation of CRISPR/Cas12a trans-cleavage kinetics via split-activator extensions.Nucleic acids research · 2026Article
- Physical stimuli-responsive CRISPR-Cas9 systems for spatiotemporally precise control of genome engineering.Theranostics · 2026Review
- Bio-orthogonal chemistry-based strategy to Turn-OFF CRISPR-Cas9 activity in solution and live cells.NAR molecular medicine · 2026Article
- Light-Activated Molecules Targeting G-Quadruplex Nucleic Acids.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Review
- Conditional Control of CRISPR/Cas9 Function by Chemically Modified Oligonucleotides.Molecules (Basel, Switzerland) · 2025Review
- Important applications of DNA nanotechnology combined with CRISPR/Cas systems in biotechnology.RSC advances · 2025Review
- Regulation of CRISPR trans-cleavage activity by an overhanging activator.Nucleic acids research · 2025Article
- Expanding Cas12a Activity Control with an RNA G-Quadruplex at the 5' end of CRISPR RNA.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Direct repeat region 3' end modifications regulate Cas12a activity and expand its applications.Nucleic acids research · 2025Article
- Emerging applications of gene editing technologies for the development of climate-resilient crops.Frontiers in genome editing · 2025Review
- Modular CRISPR/Cas12a synergistic activation platform for detection and logic operations.Nucleic acids research · 2024Article
- Unmodificated stepless regulation of CRISPR/Cas12a multi-performance.Nucleic acids research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRISPR (clustered regularly interspaced short palindromic repeats) technology holds tremendous promise for gene regulation and editing. However, precise control of CRISPR editing is essential to overcome its uncontrollable reaction process and excessive activity that leads to off-target editing. To overcome this problem, we engineered a photoswitch on G-quadruplex gRNA (GqRNA) for precisely controlled gene editing and expression by embedding dicationic azobenzene derivatives (AZD++). Our results demonstrated that rational design of the G-quadruplex onto crRNA conferred higher stability and sequence recognition specificity than unmodified single guide (sgRNA). Light-induced isomerization of AZD++ quickly transformed the on state of GqRNA, which facilitated rapid activation of ribonucleoprotein activity for genome editing of on-target sites in cells with excellent editing efficiency. In turn, AZD++-GqRNA promptly refolded to an off state to inhibit genomic cleavage, and limited the generation of off-target effects and by-products. Therefore, the proposed strategy of a photo-reversible modality presents a new opportunity for CRISPR-Cas9 modulation to improve its safety and applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.